Bard Indrevoll

USPTO Granted Patents = 10 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 2.8

ph-index = 3

Forward Citations = 22(Granted Patents)

Location History:

Olso, NO (2015)
Oslo, NO (2009 - 2020)

Company Filing History:

7 out of 189

Ge Healthcare Limited

where one patent can have more than one assignee

Years Active: 2009-2020

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10548995 - Radiolabelling method (2020-02-04),

2. 10201625 - Radiolabelled octreotate analogues as PET tracers (2019-02-12),

3. 9493504 - Radioconjugation method (2016-11-15),

4. 9259496 - Technetium labelled peptides (2016-02-16),

5. 9061080 - HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA (2015-06-23),

6. 8404802 - Peptide-based compounds (2013-03-26),

7. 8299030 - Peptide-based compounds (2012-10-30),

8. 7785566 - Pharmaceutical compounds (2010-08-31),

9. 7608243 - Fluorescein-labelled peptides (2009-10-27),

10. 7521419 - Peptide-based compounds (2009-04-21),

Title: Bard Indrevoll: Innovator in Radiopharmaceuticals

Introduction

Bard Indrevoll is a prominent inventor based in Oslo, Norway. He has made significant contributions to the field of radiopharmaceuticals, holding a total of 10 patents. His work focuses on innovative methods for in vivo imaging, particularly in the development of radiolabelled compounds.

Latest Patents

One of his latest patents is a radiolabelling method that relates to the field of radiopharmaceuticals for in vivo imaging. This invention provides a method for labelling a biological targeting molecule with the radioisotope F. It includes the preparation of lyophilised compositions of aminooxy-functionalised biomolecules, as well as radiolabelling methods using purified materials. The invention is particularly suitable for use with automated synthesizer apparatuses.

Another notable patent involves radiolabelled octreotate analogues as PET tracers. This invention describes novel radiotracers for Positron Emission Tomography (PET) imaging, specifically targeting neuroendocrine tumors. The patent details novel [18F]Fluoroethyltriazol-[Tyr3]Octreotate analogs that target somatostatin receptors found on the cell surface of gastroenteropancreatic neuroendocrine tumors. It also covers intermediates, precursors, pharmaceutical compositions, methods of making, and methods of use for these novel radiotracers.

Career Highlights

Bard Indrevoll has worked with notable companies in the healthcare sector, including GE Healthcare Limited and GE Healthcare AS. His experience in these organizations has contributed to his expertise in the development of radiopharmaceuticals.

Collaborations

Throughout his career, Bard has collaborated with esteemed colleagues such as Alan Cuthbertson and Magne Solbakken. These partnerships have further enhanced his innovative work in the field.

Conclusion

Bard Indrevoll is a distinguished inventor whose contributions to radiopharmaceuticals have advanced the field of in vivo imaging. His innovative patents and collaborations reflect his commitment to improving healthcare through technology.

This text is generated by artificial intelligence and may not be accurate.